Health ❯ Pharmaceuticals

Cancer Treatment

Drug Development Prostate Cancer Clinical Trials Multiple Sclerosis Immunotherapy mRNA Technology Rare Diseases Tumor Diseases Drug Importation Leucovorin mRNA Therapies Monoclonal Antibodies Autoimmune Diseases AI Applications Drug Pipeline Trastuzumab Rezetecan Cancer Vaccine

Law Firms Urge Telix Investors Ahead of Lead‑Plaintiff Deadline in Securities Class Action

The lead‑plaintiff motion deadline is January 9, 2026 for investors pursuing claims over Telix disclosures.

Law Firms Urge Telix Investors To Seek Lead Role by Jan. 9 in Securities Class Action

Telix Securities Class Action Draws Flurry of Investor Notices Ahead of Lead-Plaintiff Deadline

Multiple Firms File Securities Class Actions Against Telix in Indiana Federal Court Over Prostate Cancer Program Disclosures

Recursion Soars on Heavy Volume as Investors Eye CEO’s AI Conference Appearance

Eli Lilly Picks Virginia for $5 Billion Bioconjugate Plant, First of Four New U.S. Sites